AVRA
  • Home
  • About
    • Who we are
    • What we do
    • The rationale for AVRA
    • A robust vaccine pipeline
    • The global and national context
    • Expected benefits
    • Governance and management
  • Key Activities
    • Antigen surveillance
    • Vaccine platform technologies
    • Adjuvant development
    • Antigen discovery
    • Animal models
    • Vaccine immunity
    • Vaccine manufacturing partners
    • Clinical trials
    • Education and training
  • People
  • Partners
  • News and Events
  • Contact
Menu
New defence against dengue and emerging mosquito-borne viruses

New defence against dengue and emerging mosquito-borne viruses

Jan 8, 2021

Doherty Institute receives MRFF funding for COVID-19 vaccine Phase I clinical trial

Doherty Institute receives MRFF funding for COVID-19 vaccine Phase I clinical trial

Jan 3, 2021

Improving vaccination rates by dispelling mistrust and conspiracy

Improving vaccination rates by dispelling mistrust and conspiracy

Dec 17, 2020

Sydney to undertake clinical studies of needle-free vaccine patch

Sydney to undertake clinical studies of needle-free vaccine patch

Nov 23, 2020

University of Sydney to advance COVID-19 DNA vaccine to human trials

University of Sydney to advance COVID-19 DNA vaccine to human trials

Sep 24, 2020

« Older Entries
Next Entries »

ENQUIRIES

P 07 3346 1623  |  M 0499 880 791

The University of Queensland Logo The University of Sydney Logo The University of Melbourne Logo

© 2020 Australian Vaccine Response Alliance (AVRA)